From Fragmentation to Flywheel: Why South Florida Could Be the Next Strategic Biotech Hub

March 02, 2026
As biotech companies compete for talent, capital, and speed to value, geographic strategy has become a source of competitive advantage. South Florida has experienced an influx of seasoned operators, rapid expansion of research capabilities across multiple universities, and increasing engagement from both traditional and alternative capital providers. This discussion will examine what is drawing companies and leaders to the region — including operational efficiency, talent arbitrage, access to family office and international capital, and a more coordinated academic ecosystem. Can these factors translate into a durable competitive edge outside legacy hubs — and what must align to convert momentum into a true ecosystem flywheel?
Moderator
Raquel Cabo
Raquel Cabo, Founder - Miami Biotech Collective
Speakers
Mani Foroohar
Mani Foroohar, Senior Managing Director, Genetic Medicines - Leerink Partners
Kerri-Ann Miller
Kerri-Ann Miller, Chief Financial Officer - Syncromune
William Silverman
William Silverman, Executive Director, Coulter Program & New Ventures - University of Miami
Steve Squinto
Steve Squinto, Chief Investment Officer - J.P. Morgan Life Science Private Capital
Lucy To
Lucy To, EVP & Chief Financial Officer - SAB Bio